XERIS Pharmaceuticals Inc (XERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The companys proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. Its products are used for various therapeutic areas, including severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar control. The company caters caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

XERIS Pharmaceuticals Inc (XERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
Partnerships 19
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Equity Offering 21
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc - Key Competitors 23
XERIS Pharmaceuticals Inc - Key Employees 24
XERIS Pharmaceuticals Inc - Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights 26
Corporate Communications 27
Sep 07, 2017: Xeris Pharmaceuticals Appoints John P. Schmid to Board of Directors 27
Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 28
Product News 29
06/16/2017: Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program 29
02/15/2018: Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia 31
Clinical Trials 32
Aug 17, 2018: Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon 32
Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus 33
Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen 34
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List Of Tables


XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc, Key Competitors 23
XERIS Pharmaceuticals Inc, Key Employees 24

List Of Figures


XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

XERIS Pharmaceuticals Inc (XERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The companys proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous

USD 250 View Report

XERIS Pharmaceuticals Inc (XERS) - Medical Equipment - Deals and Alliances Profile

XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The companys proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous

USD 250 View Report

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Cannabics Pharmaceuticals Inc (CNBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available